Indivior Announces Special Dividend Ahead of Supernus Merger
I'm LongbridgeAI, I can summarize articles.Indivior declared a special $8.13/share cash dividend contingent on its merger with Supernus Pharmaceuticals, expected to close around November 2, 2026. The payout targets existing Indivior shareholders, excluding those receiving shares in the merger. Most of the dividend is expected to be treated as a return of capital for tax purposes. Analysts maintain a 'Buy' rating with a $43 price target, while AI analysis rates the stock as Neutral due to mixed financial metrics but positive merger synergy outlooks.
The latest announcement is out from Indivior ( (INDV) ).
On September 17, 2026, Indivior’s board declared a special cash dividend of $8.13 per share for shareholders of record as of October 30, 2026, and for certain equity award holders upon vesting. The dividend is contingent on the closing of Indivior’s merger with Supernus Pharmaceuticals, expected around November 2, 2026, with payment anticipated to be made to eligible record holders on or about November 6, 2026.
Supernus stockholders will not receive this dividend on any Indivior shares issued as merger consideration, sharply distinguishing the benefit for current Indivior investors. The company expects that at least a majority of the payout will exceed its earnings and profits, so much of the distribution may be treated as a return of capital and then capital gain for U.S. shareholders, underscoring both the deal’s significance and its tax-sensitive structuring.
The most recent analyst rating on (INDV) stock is a Buy
with a $43.00 price target.
To see the full list of analyst forecasts on Indivior stock,
see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.
INDV scores in the middle primarily because financial performance is split—stronger TTM profitability is undermined by negative operating/free cash flow and negative equity. Offsetting this, earnings-call messaging around the Supernus merger is positive with clear cost-synergy targets and strong pro forma margins, while valuation appears reasonable (P/E 13.76). Technicals are neutral overall, with negative MACD balancing longer-term support above the 100/200-day averages.
To see Spark’s full report on INDV stock,
click here.
More about Indivior
Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company and a leader in long-acting injectable treatments for opioid use disorder. The company focuses on evidence-based therapies that treat opioid use disorder as a chronic but manageable brain disease, building on more than 25 years of addiction medicine research and product development.
Indivior’s market positioning centers on helping patients achieve long-term recovery with greater independence and dignity. Working with public health stakeholders and communities, it aims to expand access to opioid use disorder treatment and reinforce its role as a key player in addiction therapeutics.
On September 17, 2026, Indivior announced that its board had declared a special cash dividend of $8.13 per share for common shareholders of record as of October 30, 2026, and for certain equity award holders upon vesting. The payment is contingent on the closing of its previously announced merger with Supernus Pharmaceuticals, expected around November 2, 2026, and would be paid to eligible record holders approximately November 6, 2026.
The special dividend will not be available to Supernus stockholders on any Indivior shares they receive in the merger, underscoring that the payout is targeted at existing Indivior investors and award holders. Indivior expects at least a majority of the dividend to exceed its current and accumulated earnings and profits, meaning a significant portion may be treated for U.S. holders as a return of capital and then as capital gain, highlighting both the financial engineering around the merger and its tax implications for shareholders.
Average Trading Volume: 2,095,448
Technical Sentiment Signal: Buy
Current Market Cap: $4.04B
For an in-depth examination of INDV stock, go to TipRanks’ Overview page.